Daniela Begolo

Daniela Begolo is a Managing Director at EQT Life Sciences, where she focuses on investments in biotech startups. She serves as a director on the board of Mosanna Therapeutics, SpliceBio and Kinaset Therapeutics, and is an observer on the board of VarmX and Snipr Biome.

Prior to joining EQT, Daniela was a Principal at Inkef in Amsterdam, the Netherlands, where she focused on investments in biotech companies, as well as medtech and digital health. She was involved in investments such as Cardior Pharmaceuticals (sold to Novo Nordisk), iOnctura and Slavia BioElectronics. Prior to Inkef, Daniela was an Analyst at M Ventures in Amsterdam, the Netherlands, the CVC of Merck KGaA.

Daniela has a background in academic research, working at ZMBH, Heidelberg University, Germany, where she also obtained her PhD in Molecular Biology. She holds MSc and BSc degrees in Biotechnology from University of Padova, Italy.